{"id":89,"date":"2026-07-29T05:48:53","date_gmt":"2026-07-29T05:48:53","guid":{"rendered":"https:\/\/astinovabiolabs.com\/blog\/?p=89"},"modified":"2026-07-29T05:48:53","modified_gmt":"2026-07-29T05:48:53","slug":"mezigdomide-cc-92480-the-first-purpose-built-molecular-glue-comes-of-age","status":"publish","type":"post","link":"https:\/\/astinovabiolabs.com\/blog\/mezigdomide-cc-92480-the-first-purpose-built-molecular-glue-comes-of-age\/","title":{"rendered":"Mezigdomide (CC-92480): The First Purpose-Built Molecular Glue Comes of Age"},"content":{"rendered":"\n

Bristol Myers Squibb’s oral CELMoD is the first cereblon modulator designed from the ground up for fast, deep protein degradation \u2014 and its positive Phase 3 SUCCESSOR-2 readout signals a new standard for relapsed\/refractory multiple myeloma.<\/em><\/p>\n\n\n\n

1. Why mezigdomide is a “first-in-class, first-of-its-kind” drug<\/h2>\n\n\n\n

The immunomodulatory imide drugs (IMiDs) \u2014 thalidomide, lenalidomide, pomalidomide \u2014 were only retrospectively<\/em> understood to be molecular glues. Their protein-degrading mechanism was discovered years after they were already in the clinic. They work, but they degrade their targets slowly and incompletely, and myeloma cells eventually adapt and become refractory.<\/p>\n\n\n\n

Mezigdomide is different in a way that matters. It is a CELMoD (Cereblon E3 Ligase Modulator)<\/strong> \u2014 and it is described as the first CELMoD specifically designed for efficient and rapid protein-degradation kinetics<\/strong> to enter clinical development. In other words, it was engineered from the outset as a degrader<\/em>, with the degradation event \u2014 not simple target binding \u2014 as the optimization endpoint. Its medicinal chemists at Celgene selected it by tracking not just binding potency but how fast and how completely<\/strong> it destroys Ikaros and Aiolos.<\/p>\n\n\n\n

The payoff is direct: mezigdomide degrades Ikaros\/Aiolos more efficiently than lenalidomide or pomalidomide<\/strong>, and it retains potent, apoptosis-inducing activity in myeloma cell lines that have become resistant to those older IMiDs<\/strong>. It is the frontrunner of a rationally designed next generation, now validated by a positive Phase 3 trial.<\/p>\n\n\n\n

Mechanism of action: induced proximity, then destruction<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Mezigdomide is a textbook molecular glue. It has no meaningful activity against Ikaros\/Aiolos on its own \u2014 it manufactures<\/em> an interaction that nature never built:<\/p>\n\n\n\n

    \n
  1. Docking.<\/strong>\u00a0The glutarimide degron seats mezigdomide in the tri-tryptophan pocket of\u00a0cereblon<\/strong>, the substrate receptor of the\u00a0CRL4 (Cullin-4 RING) E3 ubiquitin ligase<\/strong>.<\/li>\n\n\n\n
  2. Induced proximity.<\/strong>\u00a0With the drug bound, the modified CRBN surface becomes complementary to the \u03b2-hairpin “G-loop” degrons of the zinc-finger transcription factors\u00a0Ikaros (IKZF1)<\/strong>\u00a0and\u00a0Aiolos (IKZF3)<\/strong>, pulling them into a\u00a0ternary complex<\/strong>\u00a0(CRBN \u2022 mezigdomide \u2022 IKZF).<\/li>\n\n\n\n
  3. Ubiquitination.<\/strong>\u00a0Held in place, the neosubstrate is polyubiquitinated by the ligase machinery.<\/li>\n\n\n\n
  4. Degradation.<\/strong>\u00a0The\u00a026S proteasome<\/strong>\u00a0recognizes the ubiquitin chain and destroys the transcription factor. Mezigdomide and CRBN are released to catalyze the next round \u2014\u00a0catalytic, sub-stoichiometric<\/strong>pharmacology.<\/li>\n\n\n\n
  5. Dual downstream effect.<\/strong>\u00a0Loss of Ikaros\/Aiolos collapses the myeloma cell’s\u00a0IRF4\u2013MYC<\/strong>\u00a0survival axis (direct, cell-autonomous killing)\u00a0and<\/em>\u00a0de-represses\u00a0IL-2 and IFN-\u03b3<\/strong>, activating T cells and NK cells (immunomodulation). Mezigdomide’s rapid, deep degradation is what lets it trigger this program even in IMiD-resistant cells.<\/li>\n<\/ol>\n\n\n\n

    Synthesis scheme: a convergent, two-fragment assembly<\/h2>\n\n\n\n

    Because mezigdomide is modular, it is built convergently<\/strong> \u2014 the CRBN-binding “warhead” and the substrate-recruiting “arm” are prepared separately and joined in a final coupling. The scheme below shows a representative route consistent with the published structure and standard glutarimide chemistry.<\/p>\n\n\n\n

    \"\"<\/figure>\n\n\n\n

    Clinical highlights<\/h2>\n\n\n\n

    SUCCESSOR-2 (Phase 3, NCT05552976).<\/strong> In its pivotal relapsed\/refractory myeloma trial, oral mezigdomide combined with carfilzomib and dexamethasone (MeziKd)<\/strong> met its primary endpoint, delivering a statistically significant and clinically meaningful improvement in progression-free survival<\/strong> versus carfilzomib\/dexamethasone alone \u2014 the readout underpinning the drug’s regulatory filings.<\/p>\n\n\n\n

    Earlier proof of concept (CC-92480-MM-001, Phase 1\/2, NEJM<\/em> 2023).<\/strong> Mezigdomide plus dexamethasone showed meaningful response rates in heavily pretreated patients \u2014 including those refractory to lenalidomide and pomalidomide, and patients previously exposed to anti-BCMA therapies \u2014 establishing the clinical case that a purpose-built degrader can work where first-generation IMiDs fail.<\/p>\n\n\n\n

    What sets it apart clinically:<\/strong><\/p>\n\n\n\n

      \n
    • Oral<\/strong>\u00a0dosing \u2014 a convenient backbone for combination regimens, unlike infused antibody or cell therapies.<\/li>\n\n\n\n
    • Activity in IMiD-resistant disease<\/strong>\u00a0\u2014 the direct clinical translation of its faster, deeper degradation.<\/li>\n\n\n\n
    • Rational combinability<\/strong>\u00a0\u2014 its dual cytotoxic + immunomodulatory action synergizes with proteasome inhibitors (carfilzomib, bortezomib), anti-CD38 antibodies, and other immune approaches.<\/li>\n<\/ul>\n\n\n\n

      The bigger picture<\/h2>\n\n\n\n

      Mezigdomide is the clinical validation of a thesis: that molecular glues can be designed<\/strong>, not merely discovered \u2014 and that optimizing for degradation kinetics<\/em> rather than binding affinity unlocks efficacy where older drugs plateau. With a positive Phase 3 behind it and its sister CELMoD iberdomide close behind in regulatory review, the CELMoD class is poised to become a new backbone of myeloma therapy \u2014 and a proof of concept that the “one-click” degrader strategy is fully programmable.<\/p>\n\n\n\n

      This article is for scientific and educational purposes and is not medical advice; treatment decisions must be made by a qualified healthcare professional with access to the full patient context.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

      Bristol Myers Squibb’s oral CELMoD is the first cereblon modulator designed from the ground up for fast, deep protein degradation \u2014 and its positive Phase 3 SUCCESSOR-2 readout signals a new standard for relapsed\/refractory multiple myeloma. 1. Why…<\/p>\n","protected":false},"author":1,"featured_media":92,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[17],"tags":[],"class_list":["post-89","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fda-approved-small-molecules"],"_links":{"self":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/89","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/comments?post=89"}],"version-history":[{"count":1,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/89\/revisions"}],"predecessor-version":[{"id":93,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/89\/revisions\/93"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media\/92"}],"wp:attachment":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media?parent=89"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/categories?post=89"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/tags?post=89"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}